Open-Label, Randomized, Multi-center Study to Evaluate the Efficacy and Tolerability of Two Topical Regimens in Subjects With Moderate to Severe Facial Photodamage Who Have Received Cosmetic Injections

Allergan2 sites in 1 country40 target enrollmentJune 4, 2018

ConditionsFacial Photodamage

Overview

Phase: N/A
Intervention: Not specified
Conditions: Facial Photodamage
Sponsor: Allergan
Enrollment: 40
Locations: 2
Primary Endpoint: Change from Baseline in Clinical grading of the full face on the Griffith's modified 10-point scale
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study will assess the efficacy and tolerability of two topical regimens (containing cosmetic human fibroblast-derived, physiologically-balanced growth factor combination products (HULK and TNS Essential Serum)

Registry

clinicaltrials.gov

Start Date

June 4, 2018

End Date

December 3, 2018

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

Allergan

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Female subjects aged 30 years and older with Fitzpatrick skin type I-VI
•Pre-elected to receive on-label facial injection(s) (i.e. neuromodulator injection and/or filler injections)
•Experienced injection patients defined as having received at least 1 facial injection in the past 2 years.
•Current users of non-physician-dispensed brand skin care products (i.e. only using products that are available at drugstores or department stores
•Good general health and free of any disease state or physical condition (e.g. psoriasis, rosacea, scars, tattoos etc.)
•Willingness to have exams and digital photos performed on the face.
•Willingness to cooperate and participate by following study requirements (including using the provided test products) for the duration of the study and to report any adverse event symptoms or reactions immediately.
•Willingness to discontinue use of their current skincare products starting at their Week 4 visit in this study.
•Willingness to not use any other products, including self-tanners, on their face for the duration of the study other than make-up with an established tolerance of at least 1 month.
•Willingness to withhold all facial treatments during the course of the study including microdermabrasion, peels, facials, laser treatments and tightening treatments.

Exclusion Criteria

•Who are nursing, pregnant, or planning to become pregnant during the study according to subject self-report.
•Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or eczema, rosacea, sunburn, open wounds, neurotic excoriations, excessive scarring, tattoos, or other skin conditions in the test areas that would interfere with the assessments of this study.
•Uncontrolled disease such as diabetes, hypertension, hyper or hypo-thyroidism, active hepatitis, immune deficiency, or autoimmune.
•Individuals who have a pre-existing or dormant dermatologic condition (e.g., psoriasis, atopic dermatitis, rosacea, skin cancer, etc.)
•Individuals who require electrolysis, waxing, or use depilatories on the face during conduct of the study.
•Individuals with any planned surgeries and/or invasive medical procedures during the course of the study
•Individuals who are currently participating in any other facial usage study or have participated in any clinical trial within 4 weeks prior to inclusion of the study.
•Subjects currently on or planning to participate on any type of research study at another facility or a doctor's office during this study.

Outcomes

Primary Outcomes

Change from Baseline in Clinical grading of the full face on the Griffith's modified 10-point scale

Time Frame: Baseline, Week 4, Week 16

Investigator will assess the following parameters on a Griffith's modified 10-point scale (0 = None, 1 to 3 = Mild, 4 to 6 = Moderate, 7 to 9 = Severe)